<SEC-DOCUMENT>0001157523-19-001946.txt : 20190904
<SEC-HEADER>0001157523-19-001946.hdr.sgml : 20190904
<ACCEPTANCE-DATETIME>20190904160550
ACCESSION NUMBER:		0001157523-19-001946
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190828
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190904
DATE AS OF CHANGE:		20190904

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SYNLOGIC, INC.
		CENTRAL INDEX KEY:			0001527599
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				261824804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37566
		FILM NUMBER:		191074614

	BUSINESS ADDRESS:	
		STREET 1:		301 BINNEY STREET
		STREET 2:		SUITE 402
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-401-9975

	MAIL ADDRESS:	
		STREET 1:		301 BINNEY STREET
		STREET 2:		SUITE 402
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mirna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20110809
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a52088189.htm
<DESCRIPTION>SYNLOGIC, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Businesswire
         Document created using EDGARfilings PROfile 6.2.1.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-weight: bold;">WASHINGTON, D.C. 20549</div>
    <div>&#160;</div>
    <div style="text-align: center;">_________________________________________________________________________________</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">&#160;FORM 8-K</div>
    <div>&#160; <br>
    </div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">CURRENT REPORT</div>
    <div>&#160; <br>
    </div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the</div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">Securities Exchange Act of 1934</div>
    <div>&#160; <br>
    </div>
    <div style="text-align: center;">Date of Report (Date of earliest event reported): <font style="font-weight: bold;">August 28, 2019</font></div>
    <div>&#160; <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SYNLOGIC, INC.</div>
    <div>&#160; <br>
    </div>
    <div style="text-align: center;">(Exact name of registrant as specified in its charter)</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z95947519f0a04b98b61c6b48e27c8859">

        <tr>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Delaware</div>
          </td>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">001-37566</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">26-1824804</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-align: center;">(State or other jurisdiction</div>
            <div style="text-align: center;">of incorporation)</div>
          </td>
          <td style="width: 30%; vertical-align: bottom; text-align: center;">
            <div>(Commission</div>
            <div>File Number)<br>
            </div>
          </td>
          <td style="width: 35%; vertical-align: bottom; text-align: center;">
            <div>(IRS Employer</div>
            <div>Identification No.)<br>
            </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.26%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">301 Binney St., Suite 402</div>
            <div style="text-align: center; font-weight: bold;">Cambridge, MA</div>
          </td>
          <td style="width: 49.68%; vertical-align: top;">
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">02142</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.26%; vertical-align: top;">
            <div style="text-align: center;">(Address of principal executive offices)</div>
          </td>
          <td style="width: 49.68%; vertical-align: top;">
            <div style="text-align: center;">(Zip Code)</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: center;">Registrant&#8217;s telephone number, including area code: <font style="font-weight: bold;">(617) 401-9975</font></div>
    <div>&#160; <br>
    </div>
    <div style="text-align: center;"><font style="font-weight: bold;">&#160;Not applicable</font><br>
      (Former Name or Former Address, if Changed Since Last Report)</div>
    <div>&#160;</div>
    <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):</div>
    <div>&#9744;&#160; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
    <div>&#9744;&#160; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
    <div>&#9744;&#160; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
    <div>&#9744;&#160; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) <br>
    </div>
    <div> <br>
    </div>
    <div>Securities registered pursuant to Section 12(b) of the Act: <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zfdd2e95af076429d87aeadede8798012">

        <tr>
          <td style="width: 40%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center;">Title of each class</div>
          </td>
          <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center;">Trading Symbol(s)</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center;">Name of each exchange on which registered</div>
          </td>
        </tr>
        <tr>
          <td style="width: 40%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center;">Common Stock</div>
          </td>
          <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center;">SYBX</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center;">The Nasdaq Capital Market</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</div>
    <div>Emerging Growth Company <font style="background-color: #FFFFFF; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
      Act. <font style="background-color: #FFFFFF; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="font-weight: bold;">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">On August 28, 2019, Todd Shegog submitted his resignation as Chief Financial Officer of Synlogic, Inc. (the "Company"), to the Company's Board of Directors, effective September 18, 2019. Mr. Shegog did not resign as a
      result of any disagreement with the Company relating to the Company's operations, policies or practices.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">The full text of the Company&#8217;s press release regarding this announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</div>
    <div><br>
    </div>
    <div><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 9.01.</font><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"> Financial Statements and Exhibits.</font></div>
    <div><font style="font-family: 'Times New Roman',Times,serif;"> </font><font style="font-family: 'Times New Roman',Times,serif;"></font></div>
    <div><font style="font-family: 'Times New Roman',Times,serif;"> <br>
      </font></div>
    <div><font style="font-family: 'Times New Roman',Times,serif;">(d)</font><font style="font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: 'Times New Roman',Times,serif;">Exhibits</font></div>
    <div><font style="font-family: 'Times New Roman',Times,serif;"> </font><br>
    </div>
    <div><a href="a52088189ex99_1.htm"><font style="font-family: 'Times New Roman',Times,serif;">99.1</font></a><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160; <a href="a52088189ex99_1.htm">Press Release dated September 4, 2019</a></font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; text-indent: 36pt; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="zf04df431d08449aeb7f36e93e351a0d2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1">
              <div>SYNLOGIC, INC.</div>
            </td>
            <td style="width: 24%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 6%;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%;">
              <div>&#160;</div>
            </td>
            <td style="width: 24%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>Date:&#160; September 4, 2019</div>
            </td>
            <td style="width: 6%;">
              <div>By:</div>
            </td>
            <td style="border-bottom: 1pt solid #000000; width: 20%;">
              <div>/s/ Todd Shegog</div>
            </td>
            <td style="width: 24%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td rowspan="1" style="width: 6%;">
              <div>Name:<br>
              </div>
            </td>
            <td rowspan="1" colspan="2">&#160;&#160;&#160;&#160; Todd Shegog&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td rowspan="1" style="width: 6%;">
              <div>Title:<br>
              </div>
            </td>
            <td rowspan="1" colspan="2">&#160;&#160;&#160;&#160; Chief Financial Officer&#160;</td>
          </tr>

      </table>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52088189ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Businesswire
         Document created using EDGARfilings PROfile 6.2.1.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <div class="bw-release">
        <h1 style="text-align: center; list-style-position:inside;FONT-SIZE: 14pt;"> <b>Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure</b> </h1>
        <div class="bw-release-body">
          <div class="bw-release-table-js bw-release-story">
            <p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--September 4, 2019--Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced
              the following two new additions to its senior leadership team: </p>
            <ul style="list-style-type: disc;">
              <li> Richard Riese, M.D., Ph.D., has been appointed to the position of Chief Medical Officer, and will assume responsibilities from current president and CEO, Aoife Brennan, M.B., Ch.B. </li>
              <li> Michael Slater, a former consultant to the Company, has been appointed to Head of Regulatory Affairs. </li>
            </ul>
            <p> Separately, the company is announcing the departure of Todd Shegog, Chief Financial Officer, effective September 18, 2019. </p>
            <p> &#8220;Richard and Michael bring expertise and many years of experience across all phases of clinical development in a broad range of rare and immunologically-based diseases, which will be key to Synlogic&#8217;s success as we advance and expand our
              Synthetic Biotic therapeutic platform,&#8221; said Dr. Brennan. &#8220;We are excited to welcome them both to the team and look forward to their contributions.&#8221; </p>
            <p> &#8220;Synlogic is a leader in developing engineered bacterial as living medicines and has demonstrated its ability to advance these novel therapeutics into clinical trials,&#8221; stated Dr. Riese. &#8220;I believe that its Synthetic Biotic platform has the
              potential to provide a novel therapeutic solution to address unmet medical need in a variety of conditions and I look forward to advancing this exciting new therapy to patients.&#8221; </p>
            <p> Dr. Riese is a physician scientist with over 15 years of experience in the pharmaceutical industry. He most recently served as Vice President, Clinical Development at Alnylam where he led clinical development projects in several areas
              across Alnylam's rare disease portfolio. Previously, he served as head of Translational Clinical Sciences in the Research Unit at Alexion, where he was responsible for the clinical development strategy of all compounds from discovery to
              proof-of-concept. He earned a Ph.D. in biophysics and an M.D. from the Medical College of Wisconsin, and a B.S. in mathematics from the University of Wisconsin-Madison. Dr. Riese carried out postdoctoral research at the Medical College of
              Wisconsin and his residency training in internal medicine at Brigham and Women&#8217;s Hospital in Boston. Dr. Riese achieved certification by the American Boards of Pulmonary Medicine, Critical Care Medicine and Internal Medicine. </p>
            <div> </div>
            <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
              <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
            <p> Mr. Slater is a senior level regulatory professional with more than 25 years of experience including hands-on preclinical and clinical regulatory strategy development from pre-investigational new drug (IND) application through drug
              approval. Mr. Slater was the Head of Regulatory Affairs and later, Development Operations at Merrimack Pharmaceuticals from 2010 to 2019. At Merrimack, Mr. Slater led the regulatory strategy resulting in the 2015 U.S. approval of Onivyde&#174;
              (irinotecan liposome injection), an orphan drug for the treatment of metastatic pancreatic cancer. In addition, he worked with Baxalta who acquired certain ex-US rights to Onyvide, to achieve approval in Europe and other countries. Prior to
              Merrimack, Mr. Slater held various regulatory roles in several biotech and pharmaceutical companies, including Millennium Pharmaceuticals, Acusphere, Inc., Anika Therapeutics, Inc., ImmuLogic Pharmaceuticals, Biogen and Hoechst
              Pharmaceuticals. With a background in applied biology, Mr. Slater also holds a B.Sc. in information science from Leeds Beckett University, UK. and is a Fellow of The Organization for Professionals in Regulatory Affairs. </p>
            <p> In addition, the Company is announcing the departure of Todd Shegog, Chief Financial Officer, who is leaving the company to pursue another opportunity. The Company has commenced a search for a new CFO. </p>
            <p> &#8220;I also want to take the opportunity to thank Todd for his contributions at Synlogic over the past three years, including leading us through the process of becoming a public company, and establishing a strong financial team and our internal
              controls and financial operations,&#8221; said Dr. Brennan. &#8220;We have appreciated his leadership and wish him all the best in his future endeavors.&#8221; </p>
            <p> <b>About Synlogic <br>
              </b>Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically
              engineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The company&#8217;s lead program, SYNB1618, targets phenylketonuria (PKU). When delivered orally, Synthetic Biotic medicines can act from the
              gut to compensate for the dysfunctional metabolic pathway and have a systemic effect, with the potential to significantly improve symptoms of disease for affected patients. The company is developing SYNB1891 as an immunostimulatory approach
              for the treatment of advanced solid tumors. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other more common diseases, including inflammatory and immune
              disorders. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit <u>www.synlogictx.com</u>. </p>
            <div> </div>
            <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
              <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
            <p> <b>Forward-Looking Statements <br>
              </b>This press release contains &#8220;forward-looking statements&#8221; that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995, including statements regarding
              Synlogic&#8217;s plans and expectations for the development of SYNB1618, SYNB1891 and its other product candidates. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations,
              future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221;
              &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;predict&#8221; and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited
              to, statements regarding the potential of Synlogic&#8217;s platform to develop therapeutics to address a wide range of diseases including: cancer, inborn errors of metabolism and inflammatory and immune disorders; the future clinical development of
              Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic&#8217;s clinical trials and availability of clinical trial data. Actual results
              could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the preclinical development process; the ability of Synlogic to protect its intellectual
              property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading &#8220;Risk Factors&#8221; in Synlogic&#8217;s filings with the SEC. The forward-looking statements contained in this press
              release reflect Synlogic&#8217;s current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements
              in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic&#8217;s view as of any date subsequent to the date hereof. </p>
          </div>
          <div class="bw-release-contact">
            <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
            <p> <b>MEDIA CONTACT: </b><br>
              Caroline Rufo, Ph.D. <br>
              MacDougall <br>
              Phone: 781-235-3060 <br>
              Email: crufo@macbiocom.com <br>
              <br>
              <b>INVESTOR CONTACT: </b><br>
              Elizabeth Wolffe, Ph.D. <br>
              Synlogic, Inc. <br>
              Phone: 617-207-5509 <br>
              Email: liz@synlogictx.com </p>
          </div>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
